These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29358464)

  • 21. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
    Scheen AJ; Delanaye P
    Diabetes Metab; 2017 Apr; 43(2):99-109. PubMed ID: 28153377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [SGLT2 inhibitor or GLP-1 receptor agonist in a type 2 diabetic patient with cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2018 Aug; 14(615):1460-1465. PubMed ID: 30136462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
    Rossello X; Yellon DM
    Int J Cardiol; 2017 Feb; 228():198-200. PubMed ID: 27865185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
    Abdul-Ghani M; DeFronzo RA; Del Prato S; Chilton R; Singh R; Ryder REJ
    Diabetes Care; 2017 Jul; 40(7):813-820. PubMed ID: 28637886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.
    Ramos M; Ustyugova A; Hau N; Lamotte M
    J Comp Eff Res; 2020 Aug; 9(11):781-794. PubMed ID: 32573253
    [No Abstract]   [Full Text] [Related]  

  • 28. Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
    Coleman RL; Gray AM; Broedl Md UC; Fitchett D; George JT; Woerle HJ; Zinman B; Holman RR
    Diabetes Obes Metab; 2020 Jul; 22(7):1151-1156. PubMed ID: 32115840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
    Sharma A; Ofstad AP; Ahmad T; Zinman B; Zwiener I; Fitchett D; Wanner C; George JT; Hantel S; Desai N; Mentz RJ
    JACC Heart Fail; 2021 Aug; 9(8):568-577. PubMed ID: 34325887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits.
    Madievsky R
    Perm J; 2018; 22():18-034. PubMed ID: 30227909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihyperglycemic agents and cardiovascular outcomes: recent insights.
    Bajaj HS; Zinman B; Verma S
    Curr Opin Cardiol; 2017 Sep; 32(5):642-650. PubMed ID: 28678048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating cardioprotective glucose-lowering medications into clinical practice.
    Mudaliar S
    Cardiovasc Endocrinol Metab; 2018 Mar; 7(1):24-27. PubMed ID: 31646275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease.
    Ehlers LH; Lamotte M; Monteiro S; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
    Diabetes Ther; 2021 May; 12(5):1523-1534. PubMed ID: 33856655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.
    Luconi M; Raimondi L; Di Franco A; Mannucci E
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1071-1078. PubMed ID: 27776917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GLP-1 receptor agonists and heart failure in diabetes.
    Scheen AJ
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S13-2S19. PubMed ID: 28431666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P; White WB
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.